Cobas c702

Blood, sampled for routine purposes, was drawn in siliconized vacuum tubes (Vacuette 9NC Coagulation sodium citrate 3.2%, Greiner Bio-One, Kremsmünster, Austria) and sent to the central laboratory. In patients without extracorporeal or mechanical circulatory support, HI, PFH levels, and plasma LDH levels were measured once per day; in patients under extracorporeal or mechanical circulatory support, more measurements per day were performed during the initial postoperative period.
HI was measured for laboratory quality control purposes by assessing the absorbance of light at 570 and 600 nm using the Roche Cobas C 702 (Roche, Basel, Switzerland). PFH levels were measured using the pseudoperoxidase method [17 (link)] and plasma LDH levels were measured by determining the catalytic activity via the reduction of NAD to NADH and photometric measurement (Roche Cobas C 702).

Serum vancomycin levels were assessed using the kinetic interaction of microparticles in solution (KIMS) method on the Roche Cobas c702 analyzer (Roche, Basel, Switzerland). A competitive reaction takes place between the vancomycin-macromolecule conjugate and vancomycin in the serum to bind with the vancomycin antibody on the microparticles. The turbidity induced by the binding of the vancomycin conjugate to the antibody on the microparticles is measured photometrically, and this measurement is inhibited by the presence of vancomycin in the sample. The resulting turbidity is indirectly proportional to the amount of vancomycin present in the sample. The lower limit of quantitation for vancomycin is 4.0 μg/mL, determined as the lowest concentration that meets a total error goal of 20%.
CRP concentrations were determined through a particle-enhanced immunoturbidimetric assay on the Roche Cobas c702 as well. Serum creatinine levels were measured by a rate-blanked compensated kinetic Jaffe method on the Atellica CH 930 Analyzer (Siemens Healthcare Diagnostics, Marburg, Germany).

Measurement of cardiometabolic parameters was conducted based on previous studies (Jung et al., 2020a (link)). All cardiometabolic parameters (TC, HDL-C, LDL-C, TG, FFA, glucose, and insulin levels; HOMA-IR; and HOMA-β) were analyzed by the Seegene Medical Foundation (an organization certified by the Korean government). Eight milliliters of venous blood was collected in a serum separating tube (SST). Clot formation was ensured in the SST by centrifuging the sample at 3500 rpm for 10 min. TC level was determined using an enzymatic kinetic assay using Cobas C702 (Roche, Mannheim, Germany). HDL-C and LDL-C levels were detected using a homogeneous enzymatic colorimetric assay using Cobas C702 (Roche, Mannheim, Germany). The glucose level was determined using an enzymatic kinetic assay using Cobas8000 C702 (Roche, Mannheim, Germany), and the insulin level was detected using an electrochemiluminescence immunoassay (ECLIA) using Cobas8000 e602 (Roche, Mannheim, Germany). HOMA-IR and HOMA-β were calculated using the following formula: HOMA-IR = [glucose (mg/dl) × insulin (μU/ml)]/405, HOMA-β = [360 × insulin (μU/ml)/glucose (mg/dl) − 63] (Jung et al., 2020a (link)).